Literature DB >> 25752850

Group C Streptococcus dysgalactiae subsp. equisimilis in south-east Brazil: genetic diversity, resistance profile and the first report of human and equine isolates belonging to the same multilocus sequence typing lineage.

Ligia Guedes Silva1, Gabrielle Limeira Genteluci1, Marcos Corrêa de Mattos1, Thaís Glatthardt1, Agnes Marie Sá Figueiredo1, Bernadete Teixeira Ferreira-Carvalho1.   

Abstract

Streptococcus dysgalactiae subsp. equisimilis (SDSE) isolates are the most common group C streptococci in humans and reports of invasive infections associated with SDSE have been increasing. Molecular epidemiology studies are an important strategy to trace the emergence and spread of possible well-fit bacterial pathogens of humans and animals. In this work, we analysed the antimicrobial and clonal profiles of 115 SDSE infection and colonization isolates of human and equine origin. PFGE revealed the spread of two main clusters: clone A (57.4%) and clone A (26.1%). Remarkably, two isolates from clone B obtained from human colonization cases displayed identical PFGE patterns to those of three equine infection isolates. In addition, multilocus sequence typing allocated these isolates to ST129 (CC31). All of the SDSE isolates were susceptible to penicillin, vancomycin, gentamicin, levofloxacin and chloramphenicol. Tetracycline and erythromycin resistance rates were 65.2 and 13.9% respectively. Nevertheless, none of the isolates displaying sporadic PFGE patterns showed erythromycin resistance. The majority of erythromycin-resistant isolates from clone A had inducible resistance to macrolides, lincosamines and streptogramins B (iMLSB phenotype), which is associated with the presence of the ermA gene, whereas the resistant isolates from clone B showed the M phenotype, associated with the mefA gene. In conclusion, the data indicated that the analysed collection of SDSE isolates displayed a clonal structure and that the isolates found in human colonization cases could also be involved in equine infections.
© 2015 The Authors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25752850     DOI: 10.1099/jmm.0.000052

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  6 in total

1.  Beta-hemolytic Streptococcus dysgalactiae strains isolated from horses are a genetically distinct population within the Streptococcus dysgalactiae taxon.

Authors:  Marcos D Pinho; Erdal Erol; Bruno Ribeiro-Gonçalves; Catarina I Mendes; João A Carriço; Sandra C Matos; Silvia Preziuso; Antina Luebke-Becker; Lothar H Wieler; Jose Melo-Cristino; Mario Ramirez
Journal:  Sci Rep       Date:  2016-08-17       Impact factor: 4.379

2.  Pathologic and molecular characterization of Streptococcus dysgalactiae subsp. equisimilis infection in neonatal piglets.

Authors:  Sang-Ik Oh; Jong Wan Kim; Ji-Youl Jung; Myeongju Chae; Yu-Ran Lee; Jong Ho Kim; ByungJae So; Ha-Young Kim
Journal:  J Vet Sci       Date:  2018-03-31       Impact factor: 1.672

Review 3.  Pathogenicity of Virulent Species of Group C Streptococci in Human.

Authors:  Marta Kłos; Jadwiga Wójkowska-Mach
Journal:  Can J Infect Dis Med Microbiol       Date:  2017-06-12       Impact factor: 2.471

4.  Potential Factors Enabling Human Body Colonization by Animal Streptococcus dysgalactiae subsp. equisimilis Strains.

Authors:  Marcin Ciszewski; Eligia M Szewczyk
Journal:  Curr Microbiol       Date:  2017-03-18       Impact factor: 2.188

5.  Tetracycline, Macrolide and Lincosamide Resistance in Streptococcus canis Strains from Companion Animals and Its Genetic Determinants.

Authors:  Ilona Stefańska; Ewelina Kwiecień; Magdalena Kizerwetter-Świda; Dorota Chrobak-Chmiel; Magdalena Rzewuska
Journal:  Antibiotics (Basel)       Date:  2022-07-31

6.  Molecular subtyping and antimicrobial susceptibility of Streptococcus dysgalactiae subspecies equisimilis isolates from clinically diseased pigs.

Authors:  Sang Ik Oh; Jong Wan Kim; Jongho Kim; Byungjae So; Bumseok Kim; Ha Young Kim
Journal:  J Vet Sci       Date:  2020-07       Impact factor: 1.672

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.